CLChuhl Joo Lyu

Chuhl Joo Lyu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chuhl Joo Lyu has a total of 597 co-authors. Here are the top co-authors by number of shared publications:

  • Jung Woo Han

    Department of Pediatric Hematology-Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

    37 shared publications
  • Seung Min Hahn

    Department of Pediatric Hematology-Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

    25 shared publications
  • Hyo Sun Kim

    Division of Pediatric Hematology and Oncology, Department of Pediatrics, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea

    19 shared publications
  • Hoon Kook

    Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Korea

    15 shared publications
  • Hong Hoe Koo

    Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    14 shared publications
  • Hee Young Shin

    Neurosurgery Asan Medical Center University of Ulsan College of Medicine Seoul

    13 shared publications

Latest Publications

  • Open Access

    Real-world effectiveness of emicizumab prophylaxis in Korean patients with severe hemophilia A

    by Won Kee Ahn, Chuhl Joo Lyu, Jung Woo Han, Hugh Chul Kim, Soyon Kim, Ji Yoon Kim, Ye Jee Shim, Sung Eun Kim, Hee Jo Baek, Bo Ram Kim, et al.

  • Reduced-dose radiotherapy without chemotherapy for intracranial germinomas: Results from an Asian multicenter study

    by Chan Woo Wee, Hwa Kyung Byun, Yi-Wei Chen, Jaeho Cho, Yu-Mei Kang, Yen-Lin Liu, Dong-Seok Kim, Kyu-Won Shim, Jung Woo Han, Chuhl Joo Lyu, et al.

    Background: Long-term efficacy data supporting the use of reduced-dose radiotherapy (rdRT) alone for intracranial pure germinoma remain limited. In this study, we evaluated the long-term efficacy and safety of rdRT alone in patients with this condition. Methods: We retrospectively analyzed the data of 139 patients with intracranial pure germinoma treated with radiotherapy (RT) alone, using whole-ventricle irradiation (73.6%), whole-brain irradiation (9.3%), or craniospinal irradiation (CSI, 17.1%). Patients who had M + disease were included, whereas those treated with local RT alone were excluded. The most commonly prescribed dose to gross tumors was 30.0-30.6 Gy delivered in 15-17 fractions (median total dose, 35.5 Gy). The median extended-field (whole-ventricle, whole-brain, or craniospinal) dose was 23.4 Gy. Survival outcomes were analyzed according to total RT dose, whole-ventricle dose, RT field, and disease distribution. Results: At a median follow-up of 102 months, the 5- and 10-year event-free survival (EFS) rates were 90.0% and 88.4%, respectively, and the corresponding overall survival rates were 100.0% and 98.4%. Dose escalation beyond 30.6 Gy did not improve EFS (P = 1.000). A whole-ventricle dose of 18 Gy was not associated with inferior EFS compared with >18 Gy (P = .155). In patients with bifocal disease (suprasellar and pineal, n = 24), CSI significantly improved 5-year EFS (100.0% vs 63.3%, P = .040). In the study-defined optimal RT group (total dose ≥30 Gy, excluding bifocal disease without CSI; n = 125), the 3- and 5-year EFS rates were 94.2% and 92.4%, respectively. No grade ≥3 acute or late RT-related toxicities or secondary malignancies were observed. Conclusions: RdRT alone, administered with an appropriate dose and RT field according to disease status, provided excellent long-term tumor control with minimal toxicity. Tumor and extended-field doses of 30.6 Gy and 18 Gy, respectively, appeared adequate. A prospective phase 2 trial is planned to further validate this treatment strategy.


  • Open Access

    Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study

    by Guy Young, Pantep Angchaisuksiri, Shashikant J Apte, Renée Brown Frandsen, Anthony Kc Chan, Pratima Chowdary, Hermann Eichler, Chuhl Joo Lyu, Maria Fernanda Martinez Garcia, Tadashi Matsushita, et al.

    Concizumab is a novel non-factor-replacement therapy intended for once-daily subcutaneous prophylactic treatment of hemophilia A/B with and without inhibitors. Superiority was confirmed for concizumab compared with on-demand treatment in patients with hemophilia A/B without inhibitors (HA/HB) in the prospective, multicenter, open-label phase 3 explorer8 study. Here, longer‑term efficacy and safety results from the start of the study up to the 56-week cut-off are presented. Males aged ≥12 years with HA/HB were randomized 1:2 to no prophylaxis (group 1) or concizumab (group 2), or allocated to concizumab (groups 3/4). Assessments at the 56-week cut-off included measures of efficacy, pharmacokinetics/pharmacodynamics, and safety. The 56-week cut-off was defined as when all patients in group 2-4 had completed the visit at 56 weeks or permanently discontinued treatment. Of 148 patients in the full analysis set, 21 were randomized to no prophylaxis (group 1: HA, n=9; HB, n=12), 42 to concizumab (group 2: HA, n=18; HB, n=24) and 85 were assigned to the non-randomized concizumab groups 3/4 (HA, n=55; HB, n=30). After ≥24 weeks of treatment, 17 patients in group 1 switched to concizumab. Low median annualized bleeding rates for treated spontaneous and traumatic bleeding episodes were maintained at the 56-week cut-off in patients receiving concizumab (HA: 1.7 [interquartile range, 0.0; 4.5]; HB: 2.8 [0.0; 6.4]), consistent with 32‑week cut‑off results. Concizumab plasma concentration remained stable over time and no new safety concerns were reported. Concizumab showed longer-term efficacy in patients with HA/HB at the 56-week cut-off and was considered safe and well tolerated. ClinicalTrials.gov; NCT04082429.

  • Open Access

    The Gaucher Earlier Diagnosis Consensus point-scoring system for children and young adults: a retrospective and prospective evaluation in Korea

    by Seung Min Hahn, Minseok Kim, Youna Kim, Jiyoung Oh, Se Hee Kim, Hong Koh, Sung-Eun Kim, Nack-Gyun Chung, Ye Jee Shim, Hawk Kim, et al.

    Purpose: Gaucher disease (GD) is an autosomal recessive condition caused by insufficient glucocerebrosidase activity. The Gaucher Earlier Diagnosis Consensus (GED-C) initiative created a point-scoring system (PSS) to facilitate the early identification of GD based on significant indicators and covariables. This study aimed to evaluate the applicability and utility of the GED-C PSS in pediatric and young adult patients in Korea. Results: This study included both retrospective analysis and prospective recruitment. Subject recruitment involved 14 sites across 13 hospitals in Korea, where patients of any age meeting GED-C criteria were recruited, and blood samples were collected. Data of 513 subjects were analyzed and two patients were confirmed to have GD during prospective enrollment. The median age of participants was 10 years (range: 1 month to 40 years). Receiver operating characteristic analysis revealed a cutoff point of 6.5 for GED-C PSS (area under the curve of 0.9883) demonstrated high sensitivity (1.0) and specificity (0.97). A histogram indicated that the PSS scores of the two confirmed GD patients were distinct from those of other participants. Conclusions: The study suggests that GED-C PSS shows potential for the early diagnosis of GD, supporting its broader clinical use for both children and adults.

  • Open Access

    Characteristics and Treatment Patterns of Patients with Haemophilia B Receiving Recombinant Coagulation Factor IX

    by Young-Shil Park, Tai Ju Hwang, Sang Kyu Park, Eun Jin Choi, Jeong A Park, Hee Jo Baek, Chuhl Joo Lyu, Jae Hee Lee, Mi Kyung Kim, Ji Yoon Kim, et al.

    Introduction: In Haemophilia B, guideline-level factor IX (FIX) prophylaxis is recommended, but real-world dosing and adherence vary. Aim: To assess treatment patterns, adherence, FIX dosing, and their associations with bleeding events in Korean patients. Methods: We conducted a retrospective chart review and one-time survey of 130 Korean patients with haemophilia B treated with FIX for ≥12 months at 12 centers (June 2022–May 2023). A total of forty-seven patients (36.2%) received prophylaxis (≥90 IU/kg/week for ≥45 weeks); the remainder were managed non-prophylactically. Annualized bleeding events (ABEs) were analyzed using negative binomial regression, and monthly bleeds with a generalized linear mixed model. Covariates with p < 0.10 and clinical relevance were included in multivariable models. Results: The prophylaxis group showed significantly fewer ABEs (incidence rate ratio [IRR]: 0.383, p = 0.011). Each 100 IU/kg monthly dose increment reduced bleed risk (IRR: 0.692, p < 0.001). Adherence showed no independent association with bleeding in adjusted models. Conclusions: Bleed prevention in haemophilia B is driven more by delivered FIX exposure than by regimen label. Study-defined sustained prophylaxis remains underused and under-dosed. Individualized dosing and continuous adherence monitoring are essential to close this treatment gap and improve outcomes.

  • Open Access

    The Gaucher Earlier Diagnosis Consensus Point-Scoring System for Children and Young Adults: A Retrospective and Prospective Evaluation in Korea

    by Seung Min Hahn, Minseok Kim, Youna Kim, Jiyoung Oh, SeHee Kim, Hong Koh, Sung-Eun Kim, Nack-Gyun Chung, Ye Jee Shim, Hawk Kim, et al.

    Purpose Gaucher disease (GD) is an autosomal recessive condition caused by insufficient glucocerebrosidase activity. The Gaucher Earlier Diagnosis Consensus (GED-C) initiative created a point-scoring system (PSS) to facilitate the early identification of GD based on significant indicators and covariables. This study aimed to evaluate the applicability and utility of the GED-C PSS in pediatric and young adult patients in Korea. Results This study included both retrospective analysis and prospective recruitment. Subject recruitment involved 14 sites across 13 hospitals in Korea, where patients of any age meeting GED-C criteria were recruited, and blood samples were collected. Data of 513 subjects were analyzed and two patients were confirmed to have GD during prospective enrollment. The median age of participants was 10 years (range: 1 month to 40 years). Receiver operating characteristic analysis revealed a cutoff point of 6.5 for GED-C PSS (area under the curve of 0.9883) demonstrated high sensitivity (1.0) and specificity (0.97). A histogram indicated that the PSS scores of the two confirmed GD patients were distinct from those of other participants. Conclusions The study suggests that GED-C PSS shows potential for the early diagnosis of GD, supporting its broader clinical use for both children and adults.

  • Open Access

    Poor Mobilization-Associated Factors in Autologous Hematopoietic Stem Cell Harvest

    by Won Kee Ahn, Hyun-Jun Nam, Hae Won Lee, Seungmin Hahn, Jung Woo Han, Chuhl Joo Lyu, Sinyoung Kim, Soon Sung Kwon, Haerim Chung, Jin Seok Kim, et al.

    Peripheral blood stem cell transplantation (PBSCT) is an important therapeutic measure for both hematologic and non-hematologic diseases. For PBSCT to be successful, sufficient CD34+ cells need to be mobilized and harvested. Although risk factors associated with poor mobilization in patients with hematologic diseases have been reported, studies of patients with non-hematologic diseases and those receiving plerixafor are rare. To identify factors associated with poor mobilization, data from autologous PBSC harvest (PBSCH) in 491 patients were retrospectively collected and analyzed. A multivariate analysis revealed that in patients with a hematologic disease, an age older than 60 years (odds ratio [OR] 1.655, 95% confidence interval [CI] 1.049–2.611, p = 0.008), the use of myelotoxic agents (OR 4.384, 95% CI 2.681–7.168, p < 0.001), and a low platelet count (OR 2.106, 95% CI 1.205–3.682, p = 0.009) were associated with poor mobilization. In patients with non-hematologic diseases, a history of radiation on the pelvis/spine was the sole associated factor (OR 12.200, 95% CI 1.934–76.956, p = 0.008). Among the group of patients who received plerixafor, poor mobilization was observed in 19 patients (19/134, 14.2%) and a difference in the mobilization regimen was noted among the good mobilization group. These results show that the risk factors for poor mobilization in patients with non-hematologic diseases and those receiving plerixafor differ from those in patients with hematologic diseases; as such, non-hematologic patients require special consideration to enable successful PBSCH.


  • Open Access

    Diagnostic yield of targeted next-generation sequencing for pediatric hereditary hemolytic anemia

    by Yu Jeong Choi, Hongkyung Kim, Won Kee Ahn, Seung-Tae Lee, Jung Woo Han, Jong Rak Choi, Chuhl Joo Lyu, Seungmin Hahn, Saeam Shin

    Background: Hereditary hemolytic anemia (HHA) refers to a heterogeneous group of genetic disorders that share one common feature: destruction of circulating red blood cells (RBCs). The destruction of RBCs may be due to membranopathies, enzymopathies, or hemoglobinopathies. Because these are genetic disorders, incorporation of next-generation sequencing (NGS) has facilitated the diagnostic process of HHA. Method: Genetic data from 29 patients with suspected hereditary anemia in a tertiary hospital were retrospectively reviewed to evaluate the efficacy of NGS on hereditary anemia diagnosis. Targeted NGS was performed with custom probes for 497 genes associated with hematologic disorders. After genomic DNA was extracted from peripheral blood, prepared libraries were hybridized with capture probes and sequenced using NextSeq 550Dx (Illumina, San Diego, CA, USA). Result: Among the 29 patients, ANK1 variants were detected in five, four of which were pathogenic or likely pathogenic variants. SPTB variants were detected in six patients, five of which were classified as pathogenic or likely pathogenic variants. We detected g6pd pathogenic and spta1 likely pathogenic variants in two patients and one patient, respectively. Whole-gene deletions in both HBA1 and HBA2 were detected in two patients, while only HBA2 deletion was detected in one patient. One likely pathogenic variant in PLKR was detected in one patient, and one likely pathogenic variant in ALAS2 was detected in another. Conclusion: Here, NGS played a critical role in definitive diagnosis in 18 out of 29 patients (62.07%) with suspected HHA. Thus, its incorporation into the diagnostic workflow is crucial.


  • Open Access

    The First Korean Hemoglobinopathy With Unique Hemoglobin Electrophoresis Results Diagnosed as Hemoglobin Boras

    by Jeongyun Bae, Won Kee Ahn, Jaehyeok Jang, Hanmil Jang, Hyein Kang, John Hoon Rim, Seung Min Hahn, Jung Woo Han, Chuhl Joo Lyu, Jong-Baeck Lim

    Jeongyun Bae, M.D., Won Kee Ahn, M.D., Jaehyeok Jang, M.D., Hanmil Jang, M.D., Hyein Kang, M.D., John Hoon Rim, M.D., Ph.D., Seung Min Hahn, M.D., Jung Woo Han, M.D., Chuhl Joo Lyu, M.D., Ph.D., and Jong-Baeck Lim, M.D., Ph.D.. Ann Lab Med 2024;44:97-9. https://doi.org/10.3343/alm.2024.44.1.97